<a href="https://laohu8.com/S/PYXS">Pyxis Oncology</a> Inc. Announces Revisions to Patient Enrollment in Phase 1 Clinical Trial for Micvotabart Pelidotin (MICVO)
Pyxis Oncology Inc. has announced revisions to the patient enrollment participants for its Phase 1 monotherapy clinical trial evaluating micvotabart pelidotin, also referred to as MICVO. This trial, designated as NCT05720117, is a first-in-human, open-label, multicenter study aimed at assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MICVO in individuals with advanced solid tumors. The study includes two parts: a dose escalation phase and a dose expansion phase. The company has confirmed its previous guidance regarding the estimated number of head and neck squamous cell carcinoma patients to be enrolled in the dose expansion phase of the study, as previously disclosed in its quarterly report. Results from this trial have not yet been presented and are anticipated in the future as the trial progresses.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-101618), on August 04, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。